Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Current Deferred Revenue for 7 consecutive years, with $360000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 40.08% to $360000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $360000.0 through Dec 2025, up 40.08% year-over-year, with the annual reading at $360000.0 for FY2025, 40.08% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $360000.0 at 4D Molecular Therapeutics, roughly flat from $360000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $18.8 million in Q1 2021, with the low at $130000.0 in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $2.5 million, with a median of $1.1 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue tumbled 95.95% in 2023, then surged 911.54% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $5.1 million in 2021, then plummeted by 82.63% to $884000.0 in 2022, then crashed by 69.12% to $273000.0 in 2023, then fell by 5.86% to $257000.0 in 2024, then soared by 40.08% to $360000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $360000.0, $360000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.